Role of Elastography in the Evaluation of Liver Fibrosis
Published by American Gastroenterological Association Institute · GRADE
Summary
AI-generatedThis guideline provides evidence-based recommendations on utilizing noninvasive imaging tools, specifically vibration-controlled transient elastography (VCTE) and magnetic resonance elastography (MRE), for evaluating liver fibrosis, diagnosing cirrhosis, and ruling out varices across various chronic liver diseases.
Key Takeaways
- 1VCTE is superior to APRI and FIB-4 for detecting cirrhosis in chronic hepatitis C and B.
- 2A VCTE cutoff of 12.5 kPa is suggested to detect cirrhosis in HCV and chronic alcoholic liver disease.
- 3A VCTE cutoff of 11.0 kPa is suggested to detect cirrhosis in HBV.
- 4A post-treatment VCTE cutoff of 9.5 kPa can rule out advanced fibrosis in HCV patients who achieved sustained virologic response (SVR).
- 5VCTE cutoffs can help stratify risk for high-risk esophageal varices (19.5 kPa) and clinically significant portal hypertension before nonhepatic surgery (17.0 kPa).
- 6MRE is suggested over VCTE for detecting cirrhosis in high-risk NAFLD patients.
Key Recommendations
Question 1 and 2
- 1
In patients with chronic hepatitis C, the AGA recommends VCTE, if available, rather than other nonproprietary, noninvasive serum tests (APRI, FIB-4) to detect cirrhosis.
StrongEvidence: ModerateDiagnostic
Question 3
- 2
In patients with chronic hepatitis C, the AGA suggests a VCTE cutoff of 12.5 kPa to detect cirrhosis.
ConditionalEvidence: LowDiagnostic
Question 4
- 3
In noncirrhotic patients with HCV who have achieved SVR after antiviral therapy, the AGA suggests a post-treatment vibration controlled transient elastography cutoff of 9.5 kPa to rule out advanced liver fibrosis.
ConditionalEvidence: Very-lowDiagnostic
Question 5 and 6
- 4
In patients with chronic hepatitis B, the AGA suggests VCTE rather than other nonproprietary noninvasive serum tests (ie, APRI and FIB-4) to detect cirrhosis.
ConditionalEvidence: LowDiagnostic
Question 7
- 5
In patients with chronic hepatitis B, the AGA suggests a VCTE cutoff of 11.0 kPa to detect cirrhosis.
ConditionalEvidence: LowDiagnostic
Question 8 and 9
- 6
The AGA makes no recommendation regarding the role of VCTE in the diagnosis of cirrhosis in adults with NAFLD.
No recommendationEvidence: Knowledge gapDiagnostic
Question 10
- 7
In patients with chronic alcoholic liver disease, the AGA suggests a VCTE cutoff of 12.5 kPa to detect cirrhosis.
ConditionalEvidence: LowDiagnostic
Question 11
- 8
In patients with suspected compensated cirrhosis, the AGA suggests a vibration controlled transient elastography cutoff of 19.5 kPa to assess the need for esophagogastroduodenoscopy to identify high risk esophageal varices.
ConditionalEvidence: LowDiagnostic
Question 12
- 9
In patients with suspected chronic liver disease undergoing elective nonhepatic surgery, the AGA suggests a VCTE cutoff of 17.0 kPa to detect clinically significant portal hypertension to inform preoperative care.
ConditionalEvidence: LowDiagnostic
Question 13
- 10
In adult patients with chronic hepatitis C, the AGA suggests using VCTE rather than MRE for detection of cirrhosis.
ConditionalEvidence: Very-lowDiagnostic
Question 14
- 11
In adults with NAFLD and a higher risk of cirrhosis, the AGA suggest using MRE, rather than VCTE, for detection of cirrhosis. In adults with NAFLD and a lower risk of cirrhosis, the AGA makes no recommendation regarding the role of MRE or VCTE for detection of cirrhosis.
Conditional / No recommendationEvidence: Low / Knowledge gapDiagnostic
Scope & Objectives
Clinical Topic
Liver Fibrosis
Objectives
To provide clinicians with evidence-based guidance on the specific role of vibration-controlled transient elastography (VCTE) in clinical practice.
Target Patient Population
Adults with chronic liver disorders
Diagnostic Criteria
Diagnostic cutoffs for VCTE: 12.5 kPa for cirrhosis in HCV and alcoholic liver disease; 11.0 kPa for cirrhosis in HBV; 19.5 kPa to assess need for endoscopy for high-risk varices; 17.0 kPa for clinically significant portal hypertension; 9.5 kPa to rule out advanced fibrosis post-SVR in HCV.
Target Providers
Patient Criteria & Setting
Therapeutic Area
HepatologyGuideline Scope
Inclusion Criteria
- Adults
- Chronic hepatitis C
- Chronic hepatitis B
- Nonalcoholic fatty liver disease (NAFLD)
- Chronic alcoholic liver disease
Exclusion Criteria
- Acute alcoholic hepatitis
- Decompensated cirrhosis (for varices screening cutoff)
- Known esophageal varices or portal hypertension
Care Settings
Special Populations
Evidence Grading
System: GRADE
Recommendation Strength
Safety & Contraindications
Contraindications
- Acute hepatitis
- Alcohol abuse
- Food intake within 2-3 hours
- Congestive heart failure
- Extrahepatic cholestasis
- Limited intercostal space
- Obesity (may require XL-probe)
Monitoring Guidance
In noncirrhotic patients with HCV who have achieved sustained virologic response (SVR), a post-treatment VCTE cutoff of 9.5 kPa can be used to rule out advanced liver fibrosis and guide decisions on discharging patients from specialized liver clinics.
Authors & Contributors
Guideline Features
Learning Context
Difficulty
advanced
Exam Relevance
Learning Paths